Valneva SE Stock
€2.63
Your prediction
Valneva SE Stock
Pros and Cons of Valneva SE in the next few years
Pros
Cons
Performance of Valneva SE vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Valneva SE | 3.940% | -8.177% | -21.570% | -52.329% | -46.781% | -80.477% | -8.869% |
Nanobiotix | -3.130% | 5.882% | -2.041% | -43.321% | -28.224% | -51.161% | -42.544% |
Transgene S.A. | -2.910% | 8.268% | -5.660% | -28.941% | -17.910% | -53.586% | -40.669% |
Quantum Genomics S.A. | -17.670% | 730.000% | 158.701% | -36.962% | 13.182% | -97.922% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, the financial standing of Valneva, a company in the Biotechnology & Medical Research industry, is a mix of strengths and weaknesses. The company appears to be investing heavily in research and development, which is typical for firms in this sector. However, a thorough analysis of their financial statements reveals several key areas of concern, as well as areas of opportunity.
*Pros: *
Increased Revenue: Valneva's revenue has been steadily increasing - from 110,321,000 EUR in 2020 to 348,085,000 EUR in 2021 and 361,303,000 EUR in 2022. This positive trend indicates that the company is successfully growing its business and generating higher income.